Robert M. Goldberg of the Center for Medicine in the Public Interest writes:
Over the past two years shortages have developed for over 180 drugs, including cancer treatments. The shortfall is the result of stricter FDA regulation, government price controls on already discounted but complex drugs, and policies that discourage the use of new medications. Companies, facing lower prices, tighter regulation and increasing government control over what drugs will be used and when, are exiting the U.S. market and investing in product development in China and India where, sadly, it is easier and cheaper to produce next-generation medicines.
Read more at The American Spectator : Preventive Care, Obamacare Style.
(via FIRM)
